Table 1.
Summary of data demonstrating the evolving new paradigms of systemic treatment for R/M HNSCC over 12 years.
| Outcomes | Platinum + 5-FU (6) | Cetuximab + Platinum + 5-FU (6) | Pembrolizumab + Platinum + 5-FU (7)* |
|---|---|---|---|
| No. of patients | n = 200 | n = 222 | n = 281 |
| Overall Response Rate (95% CI) | 20% (15–25%) | 36% (29–42%) | 36.4% (not given) |
| Progression-Free Survival (mo.) | 3.3 (2.9–4.3) | 5.6 (5.0–6.0) | HR = 0.84 (95% CI, 0.69–1.02)* |
| Overall Survival in mo. (95% CI) | 7.4 (6.4–8.3) | 10.1 (8.6–11.2) | 13.6 (not given) |
| Hazard ratio for OS (95% CI) | 0.80 (0.64–0.99) | ||
| 0.65 (0.53–0.80) | |||
*
Results shown here represent the subgroup of patients whose Combined Positive Score (CPS) for PD-L1 was ≥1. The exact figure for progression-free survival was not given in the Abstract.